<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241942</url>
  </required_header>
  <id_info>
    <org_study_id>UNC-001 Vitrolife</org_study_id>
    <nct_id>NCT01241942</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability</brief_title>
  <official_title>Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitrolife</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>XVIVO Perfusion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to perfect the technique of EVLP and learn about the
      safety of transplanting lungs that have been ventilated (attached to a breathing machine or
      ventilator to deliver oxygen) and perfused with a lung perfusion solution (Steen solution™,
      made by Vitrolife). This ventilation and perfusion will be done outside the body (ex-vivo) in
      a modified cardiopulmonary bypass circuit (the kind of device used routinely during most
      heart surgeries). The purpose of performing ex-vivo lung perfusion and ventilation (EVLP) is
      to learn how well the lungs work, and whether they are likely safe to transplant.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding exhausted.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 Day Mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>The primary objective evaluated for this study is recipient mortality at 30 days post transplant. 30 day mortality is used as a standard research assessment to evaluate post transplant outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Lung Graft Dysfunction (PGD)</measure>
    <time_frame>24 and 72 hours post transplant.</time_frame>
    <description>Primary Lung Graft Dysfunction (PGD) is an indicator for significant morbidity and mortality after lung transplantation. PGD at 24 and 72 hours post LTX are secondary objectives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Time to Discharge.</time_frame>
    <description>The length of ICU stay is another standard research and clinical outcome assessment post transplant and has been selected as a secondary objective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 Ventilator/ECMO Status</measure>
    <time_frame>7 Days Post Transplant.</time_frame>
    <description>7 days ventilator or extra-corporeal membrane oxygenator (ECMO free are being evaluated as secondary objectives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient mortality at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Recipient mortality at 12 months post transplant is being evaluated as a secondary objective.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Bronchiectasis</condition>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>EVLP with STEEN Solution™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Lung transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Steen Solution™</intervention_name>
    <description>This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.</description>
    <arm_group_label>EVLP with STEEN Solution™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Lung Transplant</intervention_name>
    <description>No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.</description>
    <arm_group_label>Conventional Lung transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Lung Recipient Inclusion Criteria:

          -  A recipient must meet the following requirement to enroll into the study:

          -  Requires a single or bilateral lung transplant and is listed for lung transplant at
             UNC.

          -  Male or Female, 18 years of age or older.

          -  Subject or Subject's Representative provides a legally effective informed consent.

          -  Recipient does not have HIV, active Hepatitis or is colonized with Burkholderia
             cepacia.

          -  Potential subjects who have undergone previous lung transplants and meet all other
             inclusion criteria are eligible for study participation.

        Lung Recipient Exclusion Criteria:

          -  Recipient fails to meet standard of care requirements for lung transplant, or decides
             not to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M. Egan, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006 Jul;25(7):745-55.</citation>
    <PMID>16818116</PMID>
  </reference>
  <reference>
    <citation>Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmehag B, Gustafsson R, Johnsson P, Koul B, Lindstedt S, Lührs C, Sjöberg T, Steen S. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg. 2009 Jan;87(1):255-60. doi: 10.1016/j.athoracsur.2008.09.049.</citation>
    <PMID>19101308</PMID>
  </reference>
  <reference>
    <citation>Mason DP, Thuita L, Alster JM, Murthy SC, Budev MM, Mehta AC, Pettersson GB, Blackstone EH. Should lung transplantation be performed using donation after cardiac death? The United States experience. J Thorac Cardiovasc Surg. 2008 Oct;136(4):1061-6. doi: 10.1016/j.jtcvs.2008.04.023.</citation>
    <PMID>18954650</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, Sato M, Harwood S, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008 Dec;27(12):1319-25. doi: 10.1016/j.healun.2008.09.003.</citation>
    <PMID>19059112</PMID>
  </reference>
  <reference>
    <citation>Egan TM, Haithcock JA, Nicotra WA, Koukoulis G, Inokawa H, Sevala M, Molina PL, Funkhouser WK, Mattice BJ. Ex vivo evaluation of human lungs for transplant suitability. Ann Thorac Surg. 2006 Apr;81(4):1205-13.</citation>
    <PMID>16564244</PMID>
  </reference>
  <reference>
    <citation>Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454-9. Epub 2005 Jun 4.</citation>
    <PMID>16210116</PMID>
  </reference>
  <reference>
    <citation>Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008 Oct 15;86(7):889-94. doi: 10.1097/TP.0b013e318186ac4a. Review.</citation>
    <PMID>18852649</PMID>
  </reference>
  <reference>
    <citation>Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, Kirste GR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009 Jan 1;360(1):7-19. doi: 10.1056/NEJMoa0802289.</citation>
    <PMID>19118301</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, Sato M, Medin J, Davidson BL, de Perrot M, Waddell TK, Slutsky AS, Keshavjee S. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009 Oct 28;1(4):4ra9. doi: 10.1126/scitranslmed.3000266.</citation>
    <PMID>20368171</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Transplant</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>Bronchiectasis</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Alpha-1 Antitrypsin Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

